HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Biggadike, K. Articles by Farrow, S. N. Search for Related Content PubMed PubMed Citation Articles by Biggadike, K. Articles by Farrow, S. N.

Designing Corticosteroid Drugs for Pulmonary Selectivity

Respiratory and Inflammation Center of Excellence for Drug Discovery, GlaxoSmithKline, Stevenage, United Kingdom

Correspondence and requests for reprints should be addressed to Stuart N. Farrow, B.Sc., Ph.D., GSK, Gunnels Wood Road, Stevenage SG1 2NY, UK. E-mail stuart.n.farrow{at}gsk.com

Inhaled corticosteroids have become indispensable for the treatment of asthma and chronic obstructive pulmonary disease. Significant progress has been made toward minimizing side effects through the use of increasingly selective molecules, and through a variety of lung targeting strategies. Many of these developments have occurred in advance of a greatly improved understanding of corticosteroid biology at the molecular and pharmacologic level, and it has become clear that additional opportunities exist for the further enhancement of therapeutic index. This article discusses significant recent developments in the chemistry, biology, and pharmacology of corticosteroids, and considers the implications for the future use of inhaled corticosteroids.

Key Words: corticosteroid • asthma • antedrug • inhalation